– Presentation highlights in vitro activity across a spectrum of clinically-relevant variants as well as in vivo reduction of body weight and hyperphagia in MC4R-deficient Mutant Mice – "We're ...

Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest ...

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...

Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor ...

Statistically significant improvements in a preclinical model of severe chronic depression and despair Support for safe, extended, daily oral administration CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric ...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune ...

DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), announces a manufacturing contract ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company focused on developing novel neuroplastogenic small-molecule ...

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...

EB-003 significantly decreased context-induced freezing behavior one-hour post-dose (p 0.05) indicating a positive therapeutic effect in well-established translational rodent model for PTSD CAMBRIDGE, ...